Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the Senior Director, U.S. Forecasting, the Director, U.S. Forecasting will be responsible for developing and executing forecasting models and analyses that support product strategy, performance management, and operational planning. This role focuses on building and maintaining short-term demand forecasts and patient-based models across U.S. oncology assets, enabling manufacturing, supply chain, and commercial decision-making. The Director will partner closely with cross-functional stakeholders to align on forecast inputs, assumptions, and outputs, while ensuring high-quality, timely deliverables. As a key contributor within the U.S. Forecasting function, this individual will execute forecasting processes in alignment with the broader U.S. forecasting strategy and contribute to ongoing improvements in forecasting capabilities, tools, and data integration. This position is based at our Redwood City, CA headquarters, with flexibility for remote candidates willing to travel regularly to the office.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director